MiNK Therapeutics, Inc. — Director's Dealing 2021

Oct 21, 2021

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: MiNK Therapeutics, Inc. (INKT)
CIK: 0001840229
Period of Report: 2021-10-13

Reporting Person: Buell Jennifer (Director, See Remarks)

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	208725	Direct

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Stock Option (Right to Buy)	$0.01	2030-01-30	Common Stock (347875)		Direct
Stock Option (Right to Buy)	$3.03	2031-02-22	Common Stock (556600)		Direct
Restricted Stock Units	$0.00		Common Stock (695750)		Direct

Footnotes

F1: Represents an option to purchase shares of common stock, which vested as to 33% of the underlying shares on January 30, 2021, and with respect to the remainder, in eight equal quarterly installments thereafter, in each case, generally subject to continued employment.

F2: Represents an option to purchase shares of common stock, which vested as to 33% of the underlying shares on February 11, 2022, and with respect to the remainder, in eight equal quarterly installments thereafter, in each case, generally subject to continued employment.

F3: Represents restricted stock unit convertible into an equivalent number of shares of our common stock, which vest as to 100% of the underlying shares on September 27, 2023